8-K - Karyopharm Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Karyopharm Therapeutics Inc. entered into a private placement with RA Capital Management on March 24, 2026, issuing securities for gross proceeds of approximately $30 million, and separately sold shares under an existing market agreement for net proceeds of approximately $19.8 million. The company stated its existing liquidity, including these proceeds, is expected to fund its current operating plans into late in the third quarter of 2026.

Key Takeaways

1Entered into a Securities Purchase Agreement with RA Capital Management on March 24, 2026.

2Issued 1,030,354 shares of common stock at $6.785 per share and pre-funded warrants for up to 3,391,164 shares at $6.7849 per warrant.

3Issued accompanying warrants to purchase 4,421,518 shares of common stock with a $10.00 per share exercise price.

4The private placement closed on March 26, 2026, generating gross proceeds of approximately $30 million.

5Sold an aggregate of 2,994,441 shares of common stock under an Open Market Sale Agreement with Jefferies LLC for net proceeds of approximately $19.8 million.

6Following these transactions, the company will have 22,543,316 shares of common stock outstanding and pre-funded warrants to purchase 4,005,556 shares outstanding.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with RA Capital Management (the “Inve

Other Event

$6.79$6.78$10.00$30.0M

Exhibits (1)

8-K